Kayyem Jon Faiz
SEC-identified person · CIK 1366268 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Inhibrx Biosciences, Inc. INXB | Director | filed 2024 - 2026 |
| Biodesix INC BDSX | Director | filed 2021 - 2026 |
| Inhibrx, Inc. INBX | Director | filed 2020 - 2024 |
| Genmark Diagnostics, Inc. GNMK | Director · SVP, Research & Development | filed 2010 - 2018 |
| Zonagen INC ZONA | Officer | filed 2007 - 2008 |
| Aeolus Pharmaceuticals, INC. AOLS.OB | Officer | filed 2006 - 2006 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.